Aktis Oncology, Inc.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type other
SEC Category Emerging growth company
State of Incorporation DE
Business Address 17 DRYDOCK AVENUE, BOSTON, MA, 02210
Mailing Address 17 DRYDOCK AVENUE, BOSTON, MA, 02210
Phone 978-237-4380
Fiscal Year End 1231
EIN 852584233
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13D Beneficial ownership report (>5%) | January 20, 2026 | View on SEC |
| SCHEDULE 13D Beneficial ownership report (>5%) | January 20, 2026 | View on SEC |
| SCHEDULE 13D Beneficial ownership report (>5%) | January 15, 2026 | View on SEC |
| 3 Initial insider ownership report | January 15, 2026 | View on SEC |
| SCHEDULE 13D Beneficial ownership report (>5%) | January 14, 2026 | View on SEC |
| 4 Insider stock transaction report | January 14, 2026 | View on SEC |
| 4 Insider stock transaction report | January 14, 2026 | View on SEC |
| 4 Insider stock transaction report | January 14, 2026 | View on SEC |
| 4 Insider stock transaction report | January 12, 2026 | View on SEC |
| 4 Insider stock transaction report | January 12, 2026 | View on SEC |
IPO Filings
S-1 December 19, 2025
- Developing cutting-edge, targeted alpha-emitting radiopharmaceuticals for cancer treatment.
- Approach offers high potency and precision in destroying cancer cells with minimal harm to healthy tissue.
Insider Trading
STRONG BUY 6 insiders
9 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.